Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 10/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | PRSS12 | P56730 | 2/20 | 0.59 |
| ▸ | F10 | P00742 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | OGG1 | O15527 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13148385 | 0.80 | MAPK1 (0.63) | MAPK1MAPTSMN1; SMN2TP53RXFP1 | |
| SCHEMBL5935569 | 0.80 | MAPT (0.79) | MAPTSMN1; SMN2TP53RXFP1NPC1 | |
| Hydrochloric Acid SCHEMBL2907990 | 0.79 | MAPK1 (0.62) | MAPK1MAPTSMN1; SMN2TP53RXFP1 | |
| Iodide SCHEMBL17555183 | 0.79 | MAPK1 (0.62) | MAPK1MAPTSMN1; SMN2TP53RXFP1 | |
| SCHEMBL23353224 | 0.78 | MAPT (1.00) | MAPTSMN1; SMN2TP53RXFP1NPC1 | |
| SCHEMBL14315172 | 0.78 | MAPT (1.00) | MAPTSMN1; SMN2TP53RXFP1NPC1 | |
| SCHEMBL16562249 | 0.78 | MAPT (0.76) | MAPTSMN1; SMN2TP53RXFP1NPC1 | |
| SCHEMBL29865475 | 0.78 | MAPT (1.00) | MAPTSMN1; SMN2TP53RXFP1NPC1 | |
| SCHEMBL16562057 | 0.76 | MAPT (0.72) | MAPTSMN1; SMN2TP53RXFP1NPC1 | |
| SCHEMBL16553870 | 0.75 | MAPT (1.00) | MAPK1MAPTSMN1; SMN2TP53RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168829-B2 | Synthesis of quaternary salt compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-01 | — | — | US | disclosed |
| US-8093428-B2 | Synthesis of quaternary salt compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-10 | — | — | US | disclosed |
| US-7799824-B2 | Quaternary salt CCR2 antagonists | ORAPHARMA, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090112003-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-20090112004-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | KENVUE BRANDS LLC | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090112003-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | CCR2, CCR1, CCL11 | MAPK1 780/4885MAPT 2532/4885SMN1; SMN2 4702/4885 |
| US-20090112004-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | CCR2, CCR1, CCL11 | MAPK1 780/4885MAPT 2532/4885SMN1; SMN2 4702/4885 |
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | CCR2, CCR1, CXCR2 | MAPK1 350/4885MAPT 3346/4885SMN1; SMN2 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.